Does GastroPlus Support Similarity and Dissimilarity Factors of in vitro-in vivo Prediction in Biowaiver Studies? A Lower Strength Amlodipine As a Model Drug

Abstract

Background Many generic pharmaceutical products are currently available on the market place worldwide. Recently, there is a growing concern on the quality and efficacy of generic products. However, health care professionals such as physicians and pharmacists are in difficult situations to choose among alternatives.

Purpose The aim of this study is to assess the effectiveness of the in silico technique (Gastro Plus^®) in the biowaiver study and whether similarity and dissimilarity factors (f ₂ and f ₁ respectively) are effective in this regard.

Method The concentration of amlodipine in the sample was calculated by comparing the absorbance of the sample with that of a previously prepared amlodipine standard solution using validated HPLC method. The dissolution profile for each product (brand and generics) was constructed. The similarity (f₂) and dissimilarity (f ₁) factors were calculated for the generic product according to equation 1 and 2. GastroPlus™ software (version 9.0, Simulations Plus Inc., Lancaster, CA, USA) was used to predict the absorption profiles of amlodipine from the generic product Amlovasc^® and the reference Norvasc^®.

Conclusion These results may provide a rationale for the interchangeability between the RLD and generic version based on in vitro release profiles in silico technique especially in a lower strength dose drug.

Key words

Amlodipine - Biowaiver - In Silico - dissolution - Pharmacokinetics

• References

• 1 Toverud E-L, Hartmann K, Håkonsen H. A systematic review of physicians’ and pharmacists’ perspectives on generic drug use: What are the global challenges?. Appl Health Econ Health Policy 2015; 13: 35-45
• 2 Shraim N, Zaid AN, Malkieh N. et al. Investigation of the Interchangeability between Cefuroxime Axetil Tablets Marketed in Palestine. Is there A Quality Reason behind the Price?. PMPJ 1: 7-14
• 3 Shawahna R, Ghanem M, Ghanem A. et al. Establishing Similarity between multisource Betahestine dihydrochloride oral dosage forms using in vitro methods. Acta Pol Pharm 2015; 72: 1245-1252
• 4 FDA. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products—general considerations. Washington, DC: FDA; 2003
• 5 Reddy BBK, Karunakar A. Biopharmaceutics classification system: A regulatory approach. Dissolution Technologies 2011; 18: 31-37
• 6 FDA. "Waiver of in vivo bioavailability and bioequivalence studies for immediaterelease solid oral dosage forms based on a biopharmaceutics classification system: guidance for industry." FDA. Center for Drug Evaluation and Research (CDER) 2015
• 7 Vogelpoel H, Welink J, Amidon G. et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 2004; 93: 1945-1956
• 8 Cristofoletti R, Shah VP, Langguth P. et al. Meeting Report: International Workshop on Implementation of Biowaivers Based on the Biopharmaceutics Classification System (BCS). Dissolut Technol 2015; 22: 77-82
• 9 Tsume Y, Amidon GL. The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm 2010; 7: 1235-1243
• 10 Okumu A, DiMaso M, Lobenberg R. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. Eur J Pharm Biopharm 2009; 72: 91-98
• 11 Clavijo GA, De Clavijo I, Weart C. et al. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm 2009; 6: 40-47
• 12 Emami J. In vitro-in vivo correlation: from theory to applications. J Pharm Pharm Sci 2006; 9: 169-189
• 13 Pubchem. 2015 [cited 2015 18April]; Available from: http://pubchem.ncbi.nlm.nih.gov/compound/amlodipine#section = Solubility
• 14 Clavijo GA, De Clavijo I, Weart C. Amlodipine: A new calcium antagonist. Am J Health Syst Pharm 1994; 51: 59-68
• 15 Medscape. 2015 27 February [cited 2015 27 February ]; Available from: http://reference.medscape.com/drug/norvasc-amlodipine-342372#10
• 16 rxlist. 2014 [cited 2014 5 November ]; Available from: http://www.rxlist.com/norvasc-drug/indications-dosage.htm
• 17 WorldHealthOrganization. WHO Model list of EssentialMedicines, Oct. 2013
• 18 Elliott H, Meredith P. The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine. Postgrad Med J 1990; 67: S20-S23
• 19 Beresford A, McGibney D, Humphrey M. et al. Metabolism and kinetics of amlodipine in man. Xenobiotica 1988; 18: 245-254
• 20 Shohin I, Ramenskaya G, Vasilenko G. et al. In vitro dissolution kinetics of amlodipine tablets marketed in Russia under biowaiver conditions. Dissolut Technol 2010; 17: 20-23
• 21 PfizerLaboratories. 2014 [cited 2014 24 oct ]; Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id = 562
• 22 USP, USP 38-NF 33. Vol. 40(3). 2015
• 23 Fortunato D. Dissolution method development for immediate release solid oral dosage forms. Dissolut Technol 2005; 12: 12-14
• 24 Gupta A, Gaud RS, Ganga S. Development of discriminating dissolution method for an insoluble drug: Nisoldipine. Int J Pharm Tech Res 2010; 2: 931-939
• 25 Caron G, Ermondi G, Damiano A. et al. Ionization, lipophilicity, and molecular modeling to investigate permeability and other biological properties of amlodipine. Bioorg Med Chem 2004; 12: 6107-6118
• 26 Patel HJ, Patel JS, Desai B. et al. Permeability studies of anti hypertensive drug amlodipine besilate for transdermal delivery. Asian J Pharm Clin Res 2010; 3: 31-34
• 27 Burges R, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol 1994; 73: A2-A9
• 28 Van Zwieten P. Amlodipine: An overview of its pharmacodynamic and pharmacokinetic properties. Clin Cardiol 1994; 17 (Suppl. 03) III3-III6
• 29 McDaid D, Deasy P. Formulation development of a transdermal drug delivery system for amlodipine base. Int J Pharm 1996; 133: 71-83
• 30 Erden PE, Taşdemir İH, Kaçar C. et al. Simultaneous determination of valsartan and amlodipine besylate in human serum and pharmaceutical dosage forms by voltammetry. Int J Electrochem Sci 2014; 9: 2208-2220
• 31 Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992; 22: 22-31
• 32 Medsafe. 2015 [cited 2015 19April]; Available from: http://www.medsafe.govt.nz/profs/datasheet/n/Norvasctab.pdf
• 33 Jennifer B, Dressman CR. Oral Drug Absorption: Prediction and Assessment. Second Edition. 2nd ed. Drug and pharmaceutical scinces Vol. 193. 2010. Taylor & Francis; 450